Patents Assigned to The Beth Israel Hospital Association
  • Patent number: 6770272
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: August 3, 2004
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20030223970
    Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65° C. for 15 minutes, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
    Type: Application
    Filed: March 12, 2001
    Publication date: December 4, 2003
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventors: Terry B. Storm, Towia Libermann
  • Publication number: 20030050271
    Abstract: This invention pertains to a method of infecting an organ or a tissue other than a liver with an effective amount of a vector carrying genetic material of interest. This invention features a method of infecting kidney cells by introducing into the vasculature of a kidney a vector carrying genetic material of interest and maintaining the vector in contact with the renal vasculature for a period of time sufficient to allow infection of kidney cells with an effective amount of the vector, and under conditions which protect the kidney from ischemic damage. This method allows for infection of a significant number of renal endothelial cells. The method of the invention can be used for both in vivo and ex vivo applications.
    Type: Application
    Filed: July 10, 2002
    Publication date: March 13, 2003
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventor: Vikas Sukhatme
  • Publication number: 20030026778
    Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.
    Type: Application
    Filed: May 14, 2002
    Publication date: February 6, 2003
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20030003098
    Abstract: Disclosed are methods for inhibit rejection of a graft in a patient. The methods involve treating the graft with a molecule which binds to a co-stimulatory protein of antigen-presenting cells. Useful molecules include chimeras having enzymatically inactive polypeptides bonded to polypeptides which bind to co-stimulatory proteins of antigen-presenting cells. Also disclosed, are chimeric molecules composed of lytic IgG Fc bonded to CD2, CD28, CD40L, or CTLA-4. In addition, disclosed are methods for inhibiting rejection of a graft in a patient; the methods involve treating the brain-dead, beating heart donor of the graft, prior to removal of the graft from the donor, to render the graft less susceptible to rejection by the patient.
    Type: Application
    Filed: August 26, 2002
    Publication date: January 2, 2003
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventor: Terry B. Strom
  • Publication number: 20020173628
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Application
    Filed: May 14, 2002
    Publication date: November 21, 2002
    Applicant: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Publication number: 20020164311
    Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65° C. for 15 minutes, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
    Type: Application
    Filed: March 12, 2001
    Publication date: November 7, 2002
    Applicant: Beth Israel Hospital Association, a Massachusetts corporation
    Inventors: Terry B. Storm, Towia Libermann
  • Patent number: 6410008
    Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: June 25, 2002
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Patent number: 6403077
    Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.
    Type: Grant
    Filed: November 6, 1997
    Date of Patent: June 11, 2002
    Assignee: Beth Israel Hospital Association
    Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
  • Patent number: 6113900
    Abstract: Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as monoclonal antibodies or IL-2, optionally linked to a cytotoxin. Administration of the agents inhibits the proliferation of lymphocytes expressing the IL-2 receptor and thus mitigates unwanted immune responses.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: September 5, 2000
    Assignee: The Beth Israel Hospital Association
    Inventor: Terry B. Strom
  • Patent number: 6099542
    Abstract: The present invention provides catheter apparatus and catheterization methodology for generating an arteriovenous fistula or a veno-venous fistula on-demand between closely associated blood vessels and at a chosen anatomic site in-vivo. The catheter apparatus is preferably employed in pairs, each catheter of the pair being suitable for percutaneous introduction into and extension through a blood vessel. The catheterization methodology employs the catheter apparatus preferably in conjunction with conventional radiological techniques in order to place, verify, and confirm a proper alignment, orientation, and positioning for the catheters in-vivo prior to activating the perforation means for generating a fistula.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 8, 2000
    Assignee: Beth Israel Hospital Association Inc.
    Inventors: William E. Cohn, Ducksoo Kim
  • Patent number: 6068837
    Abstract: Methods and pharmaceutical compositions for modifying the mesothelial cells of a mammalian recipient in situ are provided. The methods include forming a mesothelial cell expression system in vivo or ex vivo and administering the expression system to the mammalian recipient (by way of the body cavities normally lined by mesothelial cells). The mesothelial cell expression system is useful for the localized and systemic delivery of therapeutic agents in situ.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: May 30, 2000
    Assignee: Beth Israel Hospital Association
    Inventors: Ty Robert Shockley, Robert William Jackman, Janice Ann Nagy
  • Patent number: 5958403
    Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: September 28, 1999
    Assignee: Beth Israel Hospital Association
    Inventors: Terry Strom, Towia Libermann
  • Patent number: 5916559
    Abstract: A method of lysing unwanted, non-malignant cells in a mammal, the cells having on their surfaces a receptor for a growth factor, and the method including administering to the mammal a cell-lysing amount of a substance characterized in that it has specific affinity for the receptor of the growth factor and has the ability to effect the lysis of the cells.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: June 29, 1999
    Assignee: The Beth Israel Hospital Association
    Inventor: Terry B. Strom
  • Patent number: 5869230
    Abstract: This invention pertains to a method of infecting an organ or a tissue other than a liver with an effective amount of a vector carrying genetic material of interest. This invention features a method of infecting kidney cells by introducing into the vasculature of a kidney a vector carrying genetic material of interest and maintaining the vector in contact with the renal vasculature for a period of time sufficient to allow infection of kidney cells with an effective amount of the vector, and under conditions which protect the kidney from ischemic damage. This method allows for infection of a significant number of renal endothelial cells. The method of the invention can be used for both in vivo and ex vivo applications.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: February 9, 1999
    Assignee: Beth Israel Hospital Association
    Inventor: Vikas P. Sukhatme
  • Patent number: 5789654
    Abstract: Disclosed a transgenic non-human mammal whose germ cells and somatic cells contain a knockout mutation in DNA encoding .beta..sub.3 -adrenergic receptor polypeptide.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: August 4, 1998
    Assignees: Beth Israel Hospital Association, Centre National de la Recherche Scientifique
    Inventors: Bradford B. Lowell, A. Donny Strosberg
  • Patent number: 5776465
    Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 7, 1998
    Assignees: Beth Israel Hospital Association, Whitehead Institute for Biomedical Research
    Inventors: Michael A. O'Donnell, Rosemary B. Duda, William C. DeWolf, Anna Aldovini, Richard A. Young
  • Patent number: 5767073
    Abstract: The sequence, molecular structure and expression of a cDNA clone, denoted D4, of human and murine origin, preferentially expressed in hematopoietic cells is described herein. The human cDNA clone has been expressed in bacteria and the predicted 24 Kd protein purified. The protein has been used in studies of its biochemical function. As predicted on the basis of sequence, D4 can function as a GDP-dissociation inhibitor of at least several small GTP-binding proteins (CDC42 and rac). The D4 protein was used to generate a polyclonal antibody specific for the protein. The human cDNA was used to obtain several full length murine genomic clones. A clone has been analyzed and sequenced to use for the construction of a gene-targeting vector to produce animals deficient in D4 through disruption of the gene by homologous recombination. These animals can then be used as models for fundamental and applied research on the GTP-binding proteins.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: June 16, 1998
    Assignee: Beth Israel Hospital Association
    Inventors: Bing Lim, Jean-Michel Lelias, Chaker N. Adra, Jone L. Ko
  • Patent number: 5717062
    Abstract: Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A.sub.13 and A.sub.17, A.sub.26 and A.sub.30, or A.sub.13 and A.sub.17 and A.sub.26 and A.sub.30.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: Beth Israel Hospital Association
    Inventors: Michael Chorev, Michael Rosenblatt
  • Patent number: 5704369
    Abstract: The present invention provides non-invasive methods for diagnosing Alzheimer's disease in a living human subject. One method employs a non-invasive automated apparatus which can continuously monitor pupil diameter size over time; repetitively measure pupil diameter size over time for a pre-chosen duration ranging from about less than 1 second to about 5 minutes; and cumulatively record size information as it is obtained over time. A second method employs an apparatus which can repetitively measure pupil constriction velocity for a pre-chosen duration both before and after stimulation by visible light. Both methods require the administration of at least one neural transmitter mediator to a targeted eye of the living subject in an amount insufficient to cause marked changes in pupil diameter size over time in a person who is not afflicted with Alzheimer's disease.
    Type: Grant
    Filed: September 22, 1995
    Date of Patent: January 6, 1998
    Assignee: Beth Israel Hospital Association, Inc.
    Inventors: Leonard Scinto, Kirk R. Daffner